Centiva Capital LP Cuts Stock Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

Centiva Capital LP lessened its position in Emergent BioSolutions Inc. (NYSE:EBS) by 62.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,544 shares of the biopharmaceutical company’s stock after selling 52,530 shares during the quarter. Centiva Capital LP owned about 0.06% of Emergent BioSolutions worth $263,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in EBS. CWM LLC grew its stake in Emergent BioSolutions by 32,706.7% during the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 4,906 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Emergent BioSolutions in the 2nd quarter valued at approximately $41,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Emergent BioSolutions by 22.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 4,409 shares during the last quarter. Verus Capital Partners LLC purchased a new position in shares of Emergent BioSolutions during the 2nd quarter worth approximately $68,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Emergent BioSolutions in the 2nd quarter valued at approximately $93,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on EBS shares. Benchmark upped their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Rodman & Renshaw reissued a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th. Finally, StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th.

Emergent BioSolutions Stock Performance

Shares of EBS stock opened at $8.57 on Thursday. The firm has a 50 day moving average of $9.38 and a two-hundred day moving average of $8.65. The stock has a market capitalization of $464.09 million, a PE ratio of -2.09 and a beta of 1.59. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.